
CAS 1192189-69-7
:Sortieren nach
Reinheit (%)
0
100
|
0
|
50
|
90
|
95
|
100
5 Produkte.
3-(4-(Aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate
CAS:Formel:C23H29N7O3Reinheit:99%Farbe und Form:SolidMolekulargewicht:451.5215LX7101 (3-(4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate
CAS:Formel:C23H29N7O3·HClMolekulargewicht:451.53 36.46LX7101
CAS:<p>LX7101 is a potent, selective, and orally bioavailable tyrosine kinase inhibitor. It inhibits the proliferation of endothelial cells (ECs) in vitro and the growth of EC-derived tumors in vivo. In both cell culture and animal models, LX7101 potently inhibits phosphodiesterase type-5 (PDE5), which is an enzyme that catalyzes the hydrolysis of cyclic guanosine monophosphate (cGMP). Inhibition of PDE5 leads to increased cGMP levels and has been shown to have therapeutic potential for the treatment of erectile dysfunction. LX7101 also blocks tyrosine kinases, which are enzymes that transmit signals from outside the cell to inside the cell. It has been shown to inhibit nerve injury in rats with peripheral nerve injury. The safety profile of LX7101 has been evaluated by toxicological studies in Sprague-Dawley rats and by clinical development in patients with cancer or cavernosal</p>Formel:C23H29N7O3Reinheit:Min. 95%Molekulargewicht:451.52 g/molLX7101
CAS:LX7101 is an effective inhibitor of LIMK and ROCK2 (IC50: 24, 1.6, and 10 nM for LIMK1, LIMK2, and ROCK2, respectively). It also inhibits PKA (IC50 <1 nM).Formel:C23H29N7O3Reinheit:99.08%Farbe und Form:SolidMolekulargewicht:451.52




